Published in Eur J Clin Pharmacol on August 23, 2015
High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother (2013) 1.02
Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol (1997) 1.01
Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol (2009) 0.99
A novel hepatitis B virus X-interactive protein: cytochrome C oxidase III. J Gastroenterol Hepatol (2006) 0.86
Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Dig Liver Dis (2013) 0.84
Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol (2013) 0.84
Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol (1998) 0.83
Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir. AIDS (2014) 0.83
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages? PLoS One (2015) 0.81
Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet (2013) 0.81
Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. Int J Antimicrob Agents (2015) 0.81
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages? PLoS One (2015) 0.81
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther (2016) 0.81
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother (2017) 0.77
Orlistat: weight lost at cost of HIV rebound. J Antimicrob Chemother (2016) 0.75
Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. J Antimicrob Chemother (2015) 0.75
Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients. Clinicoecon Outcomes Res (2014) 0.75
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. Eur J Clin Pharmacol (2015) 0.75
Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy? J Antimicrob Chemother (2016) 0.75
Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation. Hum Psychopharmacol (2016) 0.75
Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy. J Clin Virol (2015) 0.75
Renal function in HIV/HBV coinfected and HBV monoinfected patients on a long-term treatment with tenofovir in real life setting. Clin Exp Pharmacol Physiol (2016) 0.75
Effect of cobicistat on tenofovir disoproxil fumarate (TDF): what is true for TAF may also be true for TDF. J Acquir Immune Defic Syndr (2017) 0.75
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol (2017) 0.75